Added to YB: 2025-01-22
Pitch date: 2025-01-21
DAWN [bullish]
Day One Biopharmaceuticals, Inc.
+76.04%
current return
Author Info
No bio for this author
Company Info
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States.
Market Cap
$2.2B
Pitch Price
$12.23
Price Target
30.00 (+39%)
Dividend
N/A
EV/EBITDA
-14.45
P/E
-20.70
EV/Sales
11.29
Sector
Biotechnology
Category
growth
Why Day One Biopharma (DAWN) Could Be a $30+ Stock
DAWN: Oncology co. w/ FDA-approved OJEMDA for pLGG (BRAF fusions/mutations). $57M sales in <8 months. Only once-weekly oral therapy. Advantages over Novartis combo. JP Morgan est. $750M peak sales. $530M cash, $1.2B mcap. Undervalued. Milestones: earnings, DAY301 data, FIREFLY-2 readout. Target mid-30s.
Read full article (2 min)